Supernus Historical Balance Sheet

SUPN Stock

USD 36.57 0.42 1.14%

Trend analysis of Supernus Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 154.7 M, Total Stockholder Equity of 967.6 M, Property Plant And Equipment Net of 44.7 M or Retained Earnings of 506.7 M provides information on Supernus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Supernus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Supernus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Supernus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Supernus Pharmaceuticals is a good buy for the upcoming year.

Supernus Pharmaceuticals Inventory

81.28 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

About Supernus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Supernus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Supernus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Supernus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Supernus currently owns. An asset can also be divided into two categories, current and non-current.

Supernus Pharmaceuticals Balance Sheet Chart

At this time, Supernus Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 2nd of December 2024, Net Receivables is likely to grow to about 151.4 M, while Common Stock Shares Outstanding is likely to drop about 42.6 M.

Common Stock Shares Outstanding Total Assets Other Current Liab Non Current Liabilities Total Total Liab Treasury Stock

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Supernus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Supernus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from Supernus Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 2nd of December 2024, Net Receivables is likely to grow to about 151.4 M, while Common Stock Shares Outstanding is likely to drop about 42.6 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	420.6M	438.0M	41.5M	39.5M
Total Assets	1.7B	1.7B	1.3B	676.1M

Short Long Term Debt Total Total Assets

Supernus Pharmaceuticals balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock
Common Stock Shares Outstanding		0.68	0.5	0.5	0.61	0.63	0.42	0.42	0.47	-0.27	0.46	0.63	-0.14	0.64	0.7	0.93	0.6	0.41	0.58	0.47	0.91	0.61	0.53	0.69	0.45	0.94
Total Assets	0.68		0.85	0.8	0.85	0.89	0.64	0.8	0.85	-0.07	0.69	0.96	-0.47	0.95	0.92	0.65	0.85	0.75	0.84	0.8	0.88	0.97	0.86	0.99	0.8	0.65
Short Long Term Debt Total	0.5	0.85		0.5	0.7	0.59	0.34	0.93	0.56	0.16	0.77	0.75	-0.53	0.91	0.66	0.42	0.74	0.86	0.53	0.69	0.66	0.94	0.67	0.87	0.49	0.45
Other Current Liab	0.5	0.8	0.5		0.73	0.91	0.65	0.5	0.91	-0.3	0.44	0.88	-0.36	0.71	0.91	0.49	0.68	0.44	0.95	0.71	0.69	0.74	0.72	0.78	0.94	0.47
Total Current Liabilities	0.61	0.85	0.7	0.73		0.77	0.41	0.79	0.78	0.03	0.31	0.8	-0.42	0.82	0.82	0.54	0.94	0.36	0.83	0.53	0.7	0.81	0.65	0.87	0.78	0.54
Total Stockholder Equity	0.63	0.89	0.59	0.91	0.77		0.84	0.57	0.97	-0.26	0.53	0.97	-0.27	0.82	0.98	0.63	0.77	0.51	0.94	0.67	0.81	0.81	0.9	0.87	0.89	0.61
Property Plant And Equipment Net	0.42	0.64	0.34	0.65	0.41	0.84		0.27	0.82	-0.28	0.48	0.76	0.08	0.58	0.75	0.46	0.47	0.41	0.68	0.48	0.61	0.54	0.89	0.61	0.64	0.43
Net Debt	0.42	0.8	0.93	0.5	0.79	0.57	0.27		0.58	0.17	0.51	0.71	-0.61	0.85	0.62	0.3	0.83	0.68	0.58	0.56	0.55	0.88	0.61	0.82	0.53	0.32
Retained Earnings	0.47	0.85	0.56	0.91	0.78	0.97	0.82	0.58		-0.24	0.44	0.94	-0.28	0.78	0.94	0.46	0.75	0.46	0.94	0.64	0.69	0.78	0.88	0.83	0.92	0.43
Accounts Payable	-0.27	-0.07	0.16	-0.3	0.03	-0.26	-0.28	0.17	-0.24		-0.02	-0.15	-0.28	-0.03	-0.27	-0.12	0.03	0.03	-0.21	-0.01	-0.15	0.01	-0.08	-0.08	-0.15	-0.09
Cash	0.46	0.69	0.77	0.44	0.31	0.53	0.48	0.51	0.44	-0.02		0.65	-0.27	0.75	0.58	0.47	0.36	0.92	0.35	0.74	0.64	0.76	0.64	0.7	0.35	0.51
Non Current Assets Total	0.63	0.96	0.75	0.88	0.8	0.97	0.76	0.71	0.94	-0.15	0.65		-0.43	0.89	0.97	0.61	0.79	0.68	0.92	0.8	0.83	0.92	0.92	0.93	0.89	0.6
Non Currrent Assets Other	-0.14	-0.47	-0.53	-0.36	-0.42	-0.27	0.08	-0.61	-0.28	-0.28	-0.27	-0.43		-0.38	-0.31	-0.12	-0.34	-0.51	-0.4	-0.65	-0.29	-0.55	-0.29	-0.42	-0.45	-0.14
Cash And Short Term Investments	0.64	0.95	0.91	0.71	0.82	0.82	0.58	0.85	0.78	-0.03	0.75	0.89	-0.38		0.87	0.61	0.88	0.76	0.72	0.68	0.83	0.96	0.8	0.98	0.66	0.62
Net Receivables	0.7	0.92	0.66	0.91	0.82	0.98	0.75	0.62	0.94	-0.27	0.58	0.97	-0.31	0.87		0.66	0.79	0.56	0.93	0.71	0.85	0.86	0.85	0.92	0.88	0.66
Common Stock Total Equity	0.93	0.65	0.42	0.49	0.54	0.63	0.46	0.3	0.46	-0.12	0.47	0.61	-0.12	0.61	0.66		0.57	0.38	0.54	0.47	0.93	0.55	0.53	0.66	0.43	0.99
Short Term Investments	0.6	0.85	0.74	0.68	0.94	0.77	0.47	0.83	0.75	0.03	0.36	0.79	-0.34	0.88	0.79	0.57		0.41	0.76	0.43	0.73	0.81	0.66	0.89	0.67	0.56
Non Current Liabilities Total	0.41	0.75	0.86	0.44	0.36	0.51	0.41	0.68	0.46	0.03	0.92	0.68	-0.51	0.76	0.56	0.38	0.41		0.4	0.81	0.62	0.83	0.66	0.73	0.4	0.41
Inventory	0.58	0.84	0.53	0.95	0.83	0.94	0.68	0.58	0.94	-0.21	0.35	0.92	-0.4	0.72	0.93	0.54	0.76	0.4		0.69	0.73	0.77	0.8	0.81	0.97	0.53
Other Current Assets	0.47	0.8	0.69	0.71	0.53	0.67	0.48	0.56	0.64	-0.01	0.74	0.8	-0.65	0.68	0.71	0.47	0.43	0.81	0.69		0.68	0.83	0.73	0.74	0.75	0.48
Other Stockholder Equity	0.91	0.88	0.66	0.69	0.7	0.81	0.61	0.55	0.69	-0.15	0.64	0.83	-0.29	0.83	0.85	0.93	0.73	0.62	0.73	0.68		0.8	0.75	0.87	0.64	0.92
Total Liab	0.61	0.97	0.94	0.74	0.81	0.81	0.54	0.88	0.78	0.01	0.76	0.92	-0.55	0.96	0.86	0.55	0.81	0.83	0.77	0.83	0.8		0.82	0.97	0.74	0.57
Property Plant And Equipment Gross	0.53	0.86	0.67	0.72	0.65	0.9	0.89	0.61	0.88	-0.08	0.64	0.92	-0.29	0.8	0.85	0.53	0.66	0.66	0.8	0.73	0.75	0.82		0.82	0.77	0.53
Total Current Assets	0.69	0.99	0.87	0.78	0.87	0.87	0.61	0.82	0.83	-0.08	0.7	0.93	-0.42	0.98	0.92	0.66	0.89	0.73	0.81	0.74	0.87	0.97	0.82		0.75	0.66
Intangible Assets	0.45	0.8	0.49	0.94	0.78	0.89	0.64	0.53	0.92	-0.15	0.35	0.89	-0.45	0.66	0.88	0.43	0.67	0.4	0.97	0.75	0.64	0.74	0.77	0.75		0.42
Common Stock	0.94	0.65	0.45	0.47	0.54	0.61	0.43	0.32	0.43	-0.09	0.51	0.6	-0.14	0.62	0.66	0.99	0.56	0.41	0.53	0.48	0.92	0.57	0.53	0.66	0.42

Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	53.8M	53.7M	54.4M	61.7M	55.5M	42.6M
Total Assets	1.2B	1.5B	1.7B	1.7B	1.3B	676.1M
Short Long Term Debt Total	375.6M	390.3M	420.6M	438.0M	41.5M	39.5M
Other Current Liab	3.2M	226.1M	292.3M	268.7M	279.9M	293.9M
Total Current Liabilities	160.6M	245.1M	315.4M	688.0M	290.2M	154.7M
Total Stockholder Equity	595.4M	744.9M	815.9M	886.2M	921.5M	967.6M
Property Plant And Equipment Net	38.3M	37.8M	17.0M	15.2M	42.5M	44.7M
Net Debt	194.2M	101.7M	217.1M	344.8M	(33.5M)	(31.9M)
Retained Earnings	199.5M	326.5M	379.9M	481.2M	482.6M	506.7M
Accounts Payable	10.1M	6.1M	9.3M	10.5M	2.0M	1.9M
Cash	181.4M	288.6M	203.4M	93.1M	75.1M	116.1M
Non Current Assets Total	687.6M	873.7M	1.1B	968.4M	784.6M	823.8M
Non Currrent Assets Other	615K	8.0M	(36.1M)	(10.0M)	8.5M	8.9M
Cash And Short Term Investments	347.1M	422.5M	339.7M	461.3M	254.9M	201.2M
Net Receivables	87.3M	140.9M	148.9M	165.5M	144.2M	151.4M
Common Stock Total Equity	51K	52K	53K	54K	62.1K	40.8K
Short Term Investments	165.7M	133.9M	136.2M	368.2M	179.8M	98.1M
Liabilities And Stockholders Equity	1.2B	1.5B	1.7B	1.7B	1.3B	676.1M
Non Current Liabilities Total	404.3M	514.1M	557.9M	128.3M	66.0M	62.7M
Inventory	26.6M	48.3M	86.0M	91.5M	77.4M	81.3M
Other Current Assets	11.6M	37.4M	54.0M	15.8M	16.7M	11.7M
Other Stockholder Equity	388.4M	409.3M	434.3M	408.1M	439.5M	279.8M
Total Liab	564.9M	759.2M	873.3M	816.3M	356.2M	324.8M
Property Plant And Equipment Gross	38.3M	37.8M	33.4M	28.2M	28.9M	30.4M
Total Current Assets	472.6M	630.4M	601.6M	734.2M	493.1M	305.3M
Accumulated Other Comprehensive Income	7.4M	9.0M	1.5M	(3.2M)	(593K)	(563.4K)
Intangible Assets	24.8M	442.3M	784.7M	702.5M	599.9M	629.9M
Common Stock	51K	52K	53K	54K	55K	42.0K
Other Liab	28.7M	123.8M	137.4M	92.3M	106.2M	111.5M
Current Deferred Revenue	144.4M	122.4M	126.2M	49.8M	1.0	0.95
Other Assets	32.7M	259.7M	13.9M	10.9M	12.5M	11.9M
Long Term Debt	329.5M	345.2M	361.8M	379.3M	436.1M	457.9M
Short Term Debt	2.8M	12.8M	13.7M	408.8M	8.3M	7.9M
Property Plant Equipment	17.1M	37.8M	52.3M	44.1M	50.7M	53.2M
Net Tangible Assets	570.6M	302.6M	(86.4M)	66.7M	76.7M	72.9M
Good Will	24.8M	77.9M	117.5M	117.0M	134.6M	141.3M
Retained Earnings Total Equity	199.5M	326.5M	379.9M	481.2M	553.4M	581.1M
Capital Surpluse	388.4M	409.3M	434.3M	408.1M	469.3M	352.1M

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Supernus Stock

0.81	EPIX	ESSA Pharma Fiscal Year End 10th of December 2024	Pair Corr
0.69	FATE	Fate Therapeutics Trending	Pair Corr
0.55	A	Agilent Technologies Sell-off Trend	Pair Corr
0.49	VRCA	Verrica Pharmaceuticals	Pair Corr
0.44	EYEN	Eyenovia	Pair Corr

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.

The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

1.07

Revenue Per Share

11.877

Quarterly Revenue Growth

0.142

Return On Assets

0.0289

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Historical Balance Sheet

Supernus Pharmaceuticals Inventory

81.28 Million

About Supernus Balance Sheet Analysis

Supernus Pharmaceuticals Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Liab

Supernus Pharmaceuticals balance sheet Correlations

Supernus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Supernus Pharmaceuticals balance sheet Accounts

Pair Trading with Supernus Pharmaceuticals

Moving against Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Common Stock Total Equity
Net Receivables	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Liab	+ 0.97	Total Assets
Retained Earnings	+ 0.97	Total Stockholder Equity

Other Current Assets	- 0.65	Non Currrent Assets Other
Non Currrent Assets Other	- 0.61	Net Debt
Total Liab	- 0.55	Non Currrent Assets Other
Non Currrent Assets Other	- 0.53	Short Long Term Debt Total
Non Current Liabilities Total	- 0.51	Non Currrent Assets Other
Non Currrent Assets Other	- 0.47	Total Assets